EUVIMEDEUVIMED entdecken
Crossref

Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor

Krupa Thankam Philip, Kartik Dutta, Saikat Chakraborty, Birija Sankar Patro

The International Journal of Biochemistry & Cell Biology · 2023

DOI: 10.1016/j.biocel.2023.106443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2023. Verfasst von Krupa Thankam Philip und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, In…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Bhabha Atomic Research Centre, Department of Atomic Energy, Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly (ADPRibose) Polymerase inhibitor (PARPi) are clinically approved for the treatment of BRCA-mutated hereditary breast and ovarian cancers with homologous recombination (HR) deficiency, based on synthetic lethality concept. However, ∼90% of breast cancers are BRCA-wild type; they repair PARPi mediated damage through HR, leading to intrinsic de novo resistance. Hence, there is an unmet need of exploring novel targets in HR-proficient aggressive breast cancers for PARPi treatment. RECQL5 physically interacts and disrupts RAD51 from pre-synaptic filaments, aiding HR resolution, replication fork protection and preventing illegitimate recombination. In the current investigation, we show that targeted inhibition of HR by stabilization of RAD51-RECQL5 complex by a pharmacological inhibitor of RECQL5 (4a; 1,3,4-oxadiazole derivative) in the presence of PARPi [talazoparib (BMN673)] leads to abolition of functional HR with uncontrolled activation of NHEJ repair. This was assessed by GFP based NHEJ reporter assay, KU80 recruitment and in vitro NHEJ based plasmid ligation assay. Concomitant treatment with talazoparib and 4a generates copious amounts of replication stress, prolonged cell cycle arrest, extensive double strand breaks (DSBs) and mitotic catastrophe, leading to sensitization of HR-proficient breast cancers. Suppression of NHEJ activity abolishes 4a-mediated sensitization of breast cancers to PARPi treatment. Imperatively, 4a was ineffective against normal mammary epithelial cells, which expresses low RECQL5 vis-à-vis breast cancer cells. Moreover, functional inhibition of RECQL5 suppresses metastatic potential of breast cancer cells in response to PARPi. Together, we identified RECQL5 as a novel pharmacological target for expanding PARPi based treatment horizon for HR-proficient cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsBreast NeoplasmsHumansFemaleDNA End-Joining RepairBreastDNA ReplicationCell Line, TumorHomologous RecombinationRecQ Helicases

Stichwörter der Autor:innen

Homologous recombinationNHEJPARP inhibitorRAD51RECQL5Talazoparib

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsRECQL5 protein, humanRecQ Helicases

Autor:innen und Institutionen

  • Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India.
  • Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India. Electronic address: saikatc@barc.gov.in.
  • Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India. Electronic address: bisank@barc.gov.in.

Förderung

  • Bhabha Atomic Research Centre
  • Department of Atomic Energy, Government of India

Zitieren

APA

Philip, K. T., Dutta, K., Chakraborty, S., & Patro, B. S. (2023). Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor. The International Journal of Biochemistry & Cell Biology. https://doi.org/10.1016/j.biocel.2023.106443

Vancouver

Philip KT, Dutta K, Chakraborty S, Patro BS. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor. The International Journal of Biochemistry & Cell Biology. 2023. doi:10.1016/j.biocel.2023.106443

BibTeX
@article{Philip2023,
  author = {Philip, Krupa Thankam and Dutta, Kartik and Chakraborty, Saikat and Patro, Birija Sankar},
  title = {Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor},
  journal = {The International Journal of Biochemistry & Cell Biology},
  year = {2023},
  doi = {10.1016/j.biocel.2023.106443}
}
Kostenlos starten →